Tag: DES
SAVAL trial finds no gains with custom drug-eluting stents in PAD...
Day one of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain) put a strong focus on...
One-year results show “superior” primary patency rate for Eluvia DES compared...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...
New meta-analysis finds “no observed difference” in mortality between paclitaxel and...
February 2020 brings another paclitaxel device meta-analysis of randomised controlled trials in chronic limb-threatening ischaemia (CLTI) patients. Krystal Dinh (Westmead Hospital, Sydney, Australia) et...
VIVA 2019: Boston Scientific announces positive data for the Ranger DCB...
Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...
CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...
NOTE: ONLY intended for healthcare professionals outside of the USA and France.
Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...
Sirolimus has “a much wider” safety window and shows fewer local...
"Paclitaxel kills the cells in the artery wall; sirolimus simply stuns them," says Peter Gaines (Sheffield, UK). Gaines commented at the 2019 Vascular Leaders...
Customising therapy in femoropopliteal revascularisation
Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based therapies have become a mainstay in femoropopliteal revascularisation and how interventionalists...
Meta-analysis finds a higher risk of death in the long term...
New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...
Data from multiple studies support concept of low metal burden therapies...
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce restenosis rates, according to results from various Biotronik studies...
Eluvia paclitaxel-eluting vascular stent system demonstrates promising three-year freedom from revascularisation
The three-year results from the MAJESTIC trial for Boston Scientific’s Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe...
Alvimedica obtains injunction by German court against sales of Microport drug-eluting...
The Court of Dusseldorf, Germany, has recognised in full the CID-Alvimedica rights on intellectual properties regarding the principles and related technology on drug release...
Akesys and Elixir announce first human implant of the Prava bioresorbable...
Akesys Medical has announced their first clinical trial and successful implant of the Prava sirolimus-eluting bioresorbable peripheral scaffold system for the treatment of blockage...
Promising findings for novel drug-eluting peripheral stent
A new animal study, presented at EuroPCR (17–20 May, Paris), indicates that a novel, fluoropolymer-coated, self-expanding, paclitaxel-eluting peripheral stent (Eluvia, Boston Scientific) is associated...
